RBC Capital analyst Simos Simeonidis weighed in today on Sarepta Therapeutics Inc (NASDAQ:SRPT), after the FDA refused to allow competitor Santhera accelerated approval for its Duchenne muscular …
RBC Capital analyst Simos Simeonidis weighed in today on two biotech stocks, Sarepta Therapeutics Inc (NASDAQ:SRPT) and PTC Therapeutics, Inc. (NASDAQ:PTCT), following the release of the FDA Draft Document …
